News and Events
Dec 2022: Completion of short invivo trial at Mount Sinai of the device.
June 2022: Completed updated design of the SEAL device with our partners from Mount Sinai Medical Center, Bioengineering Department.
May 2020: KidneyX Redesign Dialysis Phase 2 Honorable Mention
Aug 2019: Presented at the IDEAS conference in Seattle, https://cdi.washington.edu/ideas/ on Innovation in Dialysis.
April 2019: Winner in the KidneyX Redesign Dialysis prize competition Phase 1
April 2019: 3rd Innovation & Entrepreneurship International Competition, Shenzhen, China. Third Prize, Biology and Life Technology Final
Mar 2018: Selected participant at the 1st China (Ningbo) Global Experts Summit (CGES) http://www.ocstab.net/index.php/en/activities-news/activity-details/the1st-china-ningbo-global-experts-summit-cges
Nov. 2017: Selected participant in the Global Startup Program Asia + in Taipei, Taiwan. http://www.garageplus.asia/en/startups
Mission Statement: "We believe that entrepreneurs are mission-driven individuals who take actions to realize their dreams and bring a better life to society through innovation."
May 2017: Mixiii Biomed 2017 conference, table in the Start-Up Pavilion.
April 2017: Successful completion of 9-month vascularized tissue in-growth tissue study in rodents. Study reports by an expert histopathologist, Dr. Abraham Nyska, DVM, Dipl. ECVP, Fellow IATP. Slides prepared by Alizee Pathology, Thurmont, MD.
Nov 2016: Access for Life a Silver Award Winner of MassChallenge 2016.
July 2016: Next stage of animal trials commenced at the GLPigs CRO, Assaf Harofeh Medical Center, Rishon Lezion, Israel.
May 2016: Won a place in the MassChallenge Accelerator Program in Jerusalem.
April 2016: Won a EU Horizon 2020 Phase 1 SME Grant. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 728915.
Jan. 2016: Pharmes Innovations Limited investment received, which will be used to fund the animal trials. As a result, David Grey has joined the Board of Directors.
Dec. 2015: Initial round of the large animal trials, pilot stage, completed at the GLPigs CRO at Assaf Harofeh Medical Center, Tzrifin, Israel.
May 2015: Our CEO, Philip Libman, presented at the Israel Advanced Technology Institute’s Biomed 2015 Conference in Tel Aviv.
Picture from Biomed 2017 conference. From left: Dr. Yehuda Zicherman, Eyal Teichman, Philip Libman